XML 26 R17.htm IDEA: XBRL DOCUMENT v3.23.1
Segment Reporting
 12 Months Ended
Jan. 31, 2023
Segment Reporting [Abstract]  
SEGMENT REPORTING
10.SEGMENT  REPORTING

 

We organize and manage our business by the following two segments which meet the definition of reportable segments under ASC 280-10, Segment Reporting:

 

4P Therapeutics and Pocono Pharmaceuticals. These segments are based on the customer type of products or services provided and are the same as our business units. Separate financial information is available and regularly reviewed by our chief-decision maker, who is or chief executive officer, in making resource allocation decisions for our segments. Our chief-decision maker evaluates segment performance to the GAAP measure of gross profit.

 

   January 31, 
   2023   2022 
         
Net sales        
Pocono Pharmaceuticals  $1,785,597   $1,179,620 
4P Therapeutics   294,102    242,534 
    2,079,699    1,422,154 
           
Gross profit          
Pocono Pharmaceuticals   726,702    595,087 
4P Therapeutics   23,702    (40,777)
    750,404    554,310 
           
Operating expenses          
Selling, general and administrative-Pocono Pharmaceuticals   577,930    556,204 
Selling, general and administrative-4P Therapeutics   103,181    96,079 
Corporate overhead   3,234,930    3,370,541 
Research and development-4P Therapeutics   982,227    411,383 
Goodwill impairment-Pocono Pharmaceuticals   327,326    2,180,836 
    5,225,594    6,615,043 
           
Depreciation and Amortization          
Pocono Pharmaceuticals  $264,156   $220,524 
4P Therapeutics   65,987    88,217 
   $330,143   $308,741 

  

The following table presents information about net sales and property and equipment, net of accumulated depreciation, in the United States and elsewhere.

 

   Year Ended 
   January 31, 
   2023   2022 
         
Net sales:        
United States  $2,079,699   $1,335,554 
Outside the United States   -    86,600 
   $2,079,699   $1,422,154 
           
Property and equipment, net of accumulated depreciation          
United States  $897,735   $979,297 
Outside the United States   
-
    
-
 
   $897,735   $979,297 
Assets:          
Corporate  $1,745,731   $4,750,937 
Pocono Pharmaceuticals   5,400,814    5,639,178 
4P Therapeutics   2,309,832    2,349,548 
   $9,456,377   $12,739,660